47 / 82
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 1, January/February 2018
AFRICA
45
Conclusion
Our data do not support the role of contact allergy in the
pathogenesis of in-stent restenosis.
The study was done as part of Dr Swaid’s MD thesis
References
1.
Koster R, Vieluf D, Kiehn M,
et al.
Nickel and molybdenum contact
allergies in patients with coronary in-stent restenosis.
Lancet
2000:
356
:
1895–1897.
2.
Duarte I, Amorim JR, Perizzio EF, Schmitz R. Metal contact dermati-
tis: Prevalence of sensitization to nickel, cobalt and chromium.
An Bras
Dermatol
2005:
80
(2): 137–142.
3.
Schmidt M, Goebeler M. Immunology of metal allergies.
J Dtsch
Dermatol Ges
2015:
13
: 653–660.
4.
Hillen M, Haude, R Erbel, M Goos. Evaluation of metal allergies in
patients with coronary stents.
Contact Dermatitis
2002;
47
: 353–356.
5.
Iijima R, Ikari Y, Amiya E,
et al.
The impact of metallic allergy on stent
implantation. Metal allergy and recurrence of in-stent restenosis.
Int J
Cardiol
2005;
104
: 319–325.
6.
Wilkinson D, Fregert S, Magnusson B,
et al
. Terminology of contact
dermatitis.
Acta Dermatol Venereol
1970;
50
: 287–292.
7.
Jurczyk M.
Bionanomaterials for Dental Applications
. Singapore: Pan
Stanford, 2013: 36–37.
8.
Norgaz T, Hobikoglu G, Serdar ZA,
et al
. Is There a link between nickel
allergy and coronary stent restenosis?
Tohoku J Exp Med
2005;
206
:
243–246.
9.
El-Mawardy R, Fuad H, Abdel-Salam Z,
et al
. Does nickel allergy play
a role in the development of in-stent restenosis?
Eur Rev Med Pharmacol
Sci
2011;
15
: 1235–1240
.
10. Alia
ğ
ao
ğ
lu C, Turan H, Erden I,
et al
. Relation of nickel allergy with
in-stent restenosis in patients treated with cobalt chromium stents.
Ann
Dermatol
2012;
24
: 426–429.
11. Messer RL, Wataha JC, Lewis JB,
et al
. Effect of vascular stent alloys
on expression of cellular adhesion molecules by endothelial cells.
J Long
Term Eff Med Implants
2005;
15
: 39–47.
12. Thyssen JP, Engkilde K, Menné T,
et al
. No association between metal
allergy and cardiac in-stent restenosis in patients with dermatitis-results
from a linkage study.
Contact Dermatitis
2011;
64
(3): 138–141.
13. Lazarov A, David M, Abraham D, Trattner A. Comparison of reactiv-
ity to allergens using the TRUE test and IQ chamber system.
Contact
Dermatitis
2007;
56
: 140–145.
14. Ingber A, Gaamelgaard B, David M. Detergents and bleaches are
sources of chromium contact dermatitis in Israel.
Contact Dermatitis
1998;
38
: 101–104.
15. Geier J, Uter W, Lessmann H, Schnuch A. Current contact alergens.
Hautarzt
2011;
62
: 751–756.
16. Zug KA, Warsaw EM, Fowler JF,
et al
. Patch test results of the North
American Contact Dermatitis group 2005–2006.
Dermatitis
2009;
20
:
149–160.
17. Schneider K, Akkan Z. Quantitative relationship between the local
lymph node assay and human skin sensitization assays.
Regul Toxicol
Pharmacol
2004;
39
: 245–255.
Dynaval: new product launch
Pharma Dynamics, South Africa’s leading supplier of
cardiovascular medicines, announces the addition of Dynaval
(valsartan) to its extensive range of cardiovascular medicines.
Dynaval is indicated:
•
for the treatment of mild to moderate hypertension
•
to improve survival following myocardial infarction
•
for the treatment of heart failure (NYHA class II–IV).
Dynaval is available in 80- and 160-mg tablets and is the only
valsartan brand conveniently packed in 30 tablets.
Product
Active
Pack size
Price
(SEP excl VAT)
Dynaval 80 mg
valsartan 80 mg
30 tabs
R92.66
Dynaval 160 mg valsartan 160 mg
30 tabs
R92.66
For further information, kindly contact Afzal Dhansay, Group
Product Manager: Cardiovascular at (021) 707-7000.
Drug Trends in Cardiology